Antiphospholipid Syndrome (APS) is an acquired autoimmune thrombophilia characterised by persistent antiphospholipid antibodies (aPL) causing arterial/venous thrombosis and/or obstetric complications. The Sapporo criteria (1998), revised as the Sydney criteria (2006), established the international consensus definition requiring at least one clinical criterion (thrombosis or pregnancy morbidity) and one laboratory criterion (LA, aCL, or anti-β2GPI positive on two occasions ≥12 weeks apart). The triple-positive profile (all three antibodies positive) confers the highest thrombotic recurrence risk and is a key driver of treatment decisions — warranting warfarin over DOACs based on multiple randomised trials demonstrating DOAC inferiority in this group.